JP2014527073A5 - - Google Patents

Download PDF

Info

Publication number
JP2014527073A5
JP2014527073A5 JP2014530158A JP2014530158A JP2014527073A5 JP 2014527073 A5 JP2014527073 A5 JP 2014527073A5 JP 2014530158 A JP2014530158 A JP 2014530158A JP 2014530158 A JP2014530158 A JP 2014530158A JP 2014527073 A5 JP2014527073 A5 JP 2014527073A5
Authority
JP
Japan
Prior art keywords
alkyl
halogen
group
alkoxy
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014530158A
Other languages
English (en)
Japanese (ja)
Other versions
JP5815874B2 (ja
JP2014527073A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/067469 external-priority patent/WO2013037703A1/en
Publication of JP2014527073A publication Critical patent/JP2014527073A/ja
Publication of JP2014527073A5 publication Critical patent/JP2014527073A5/ja
Application granted granted Critical
Publication of JP5815874B2 publication Critical patent/JP5815874B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014530158A 2011-09-12 2012-09-07 Hdlコレステロール上昇剤としての3−ピリジンカルボン酸ヒドラジド Expired - Fee Related JP5815874B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11180929 2011-09-12
EP11180929.9 2011-09-12
PCT/EP2012/067469 WO2013037703A1 (en) 2011-09-12 2012-09-07 3 -pyridine carboxylic acid hydrazides as hdl-cholesterol raising agents

Publications (3)

Publication Number Publication Date
JP2014527073A JP2014527073A (ja) 2014-10-09
JP2014527073A5 true JP2014527073A5 (enExample) 2015-07-16
JP5815874B2 JP5815874B2 (ja) 2015-11-17

Family

ID=46796631

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014530158A Expired - Fee Related JP5815874B2 (ja) 2011-09-12 2012-09-07 Hdlコレステロール上昇剤としての3−ピリジンカルボン酸ヒドラジド

Country Status (10)

Country Link
US (1) US8648099B2 (enExample)
EP (1) EP2755953A1 (enExample)
JP (1) JP5815874B2 (enExample)
KR (1) KR20140057652A (enExample)
CN (1) CN103781765A (enExample)
BR (1) BR112014005634A2 (enExample)
CA (1) CA2844865A1 (enExample)
MX (1) MX2014001860A (enExample)
RU (1) RU2014111321A (enExample)
WO (1) WO2013037703A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104725353A (zh) * 2015-03-12 2015-06-24 佛山市赛维斯医药科技有限公司 一类含烟酸酰胺和哌啶结构ptp1b抑制剂及其用途
US20200085810A1 (en) 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005531520A (ja) * 2002-03-28 2005-10-20 メルク エンド カムパニー インコーポレーテッド 置換2,3−ジフェニルピリジン類
KR100970050B1 (ko) * 2005-04-06 2010-07-16 에프. 호프만-라 로슈 아게 Cb1 역 작용제로서 피리딘-3-카복사마이드 유도체
WO2007011760A2 (en) * 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
US7629346B2 (en) * 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
JP2010505789A (ja) * 2006-10-04 2010-02-25 エフ.ホフマン−ラ ロシュ アーゲー Hdl−コレステロール上昇剤としての3−ピリジンカルボキサミド及び2−ピラジンカルボキサミド誘導体
TW200940537A (en) * 2008-02-26 2009-10-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2012140432A5 (enExample)
JP2015143283A5 (enExample)
JP2014526533A5 (enExample)
PE20160608A1 (es) Compuestos de quinolina selectivamente sustituida
JP2015537008A5 (enExample)
JP2017523152A5 (enExample)
CY1119015T1 (el) 4'-αζιδο-3'φθορο υποκατεστημενα νουκλεοζιδιου παραγωγα ως αναστολεις αντιγραφης hcv rna
AR059622A1 (es) Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico inducibles
EA201070872A1 (ru) Производные азабициклических карбоксамидов, их получение и их применение в терапии
AR092955A1 (es) Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona
CO6150164A2 (es) Derivados de 2-metilmorfolina pirido-,pirazo-ypirimido-pirimidina como inhibidores de mtor
JP2016540742A5 (enExample)
AR096246A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
JP2016506958A5 (enExample)
JP2010504286A5 (enExample)
DOP2010000227A (es) Derivados biciclicos de carboxamidas aza-biciclicas, su preparacion y su aplicacion terapeutica
JP2016503797A5 (enExample)
JP2013010731A5 (ja) 複素環化合物
JO3037B1 (ar) N -[5-(أمينوسلفونيل)-4- ميثيل-3،1- ثيازول-2- يل]-n- ميثيل-2-[4-(2- بيريدينيل) فنيل] أسيتاميد ميسيلات مونوهيدرات
AR086100A1 (es) Compuestos de cromenona y composiciones farmaceuticas que los contienen
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
RU2021109549A (ru) ИНГИБИТОРЫ α-АМИНО-β-КАРБОКСИМУКОНАТ ε-СЕМИАЛЬДЕГИД-ДЕКАРБОКСИЛАЗЫ
EA201791816A1 (ru) Ингибиторы kv1.3 и их применение в медицине
RU2012116003A (ru) Макроциклические ингибиторы jak
CY1116388T1 (el) 5-(φαινυλο/πυριδινυλο-αιθινυλο)-2-πυριδινο/2-πυριμιδινο-καρβοξαμιδια ως mglur5 ρυθμιστες